Evidence map›Paper›PMID 36590263›Full record

ArticleJACS Au2022

Design and Synthesis of Neutralizable Fondaparinux.

Liangwei Zhang, Yating Liu, Zhuojia Xu, Tianhui Hao, Peng George Wang, Wei Zhao, Tiehai Li

Open access · goldAbstract read
In one paragraph

Article in JACS Au, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Efficient Small-Molecule Reversal Agents for Anticoagulant Fondaparinux.ACS pharmacology & translational science · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Liangwei ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yating LiuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhuojia XuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Tianhui HaoShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Peng George WangSchool of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.ORCID https://orcid.org/0000-0003-3335-6794
Wei ZhaoCollege of Pharmacy, Nankai University, Tianjin 300353, China.ORCID https://orcid.org/0000-0002-7887-2357
Tiehai LiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID https://orcid.org/0000-0002-3600-1828
Chinese Academy of Sciences · CNNanjing University of Chinese Medicine · CNNankai University · CNSouthern University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fondaparinux, a clinically approved anticoagulant pentasaccharide for the treatment of thrombotic diseases, displays better efficacy and biosafety than other heparin-based anticoagulant drugs. However, there is no suitable antidote available for fondaparinux to efficiently manage its potential bleeding risks, thereby precluding its widespread use. Herein, we describe a convergent and stereocontrolled approach to efficiently synthesize an aminopentyl-functionalized pentasaccharide, which is further used to prepare fondaparinux-based biotin conjugates and clusters. Biological activity evaluation demonstrates that the anticoagulant activity of the fondaparinux-based biotin conjugate and trimer is, respectively, neutralized by avidin and protamine as effective antidotes. This work suggests that our synthetic biotin conjugate and trimer have potential for the development of neutralizable and safe anticoagulant drugs.

Identifiers

PMID36590263
PMCPMC9795572
OpenAlexW4308967268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.